Stock TEVA TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Equities

TEVA

IL0006290147

Pharmaceuticals

Market Closed - TEL AVIV STOCK EXCHANGE
Other stock markets
 07:24:08 2024-04-25 am EDT 		5-day change 1st Jan Change
4,933 ILa +0.98% Intraday chart for Teva Pharmaceutical Industries Limited -0.90% +29.31%
Apr. 22 Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court MT
Apr. 19 Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 10,702 10,576 8,835 10,129 11,703 15,642 - -
Enterprise Value (EV) 1 35,634 34,318 29,713 28,540 28,310 30,264 27,760 25,260
P/E ratio -10.8 x -2.65 x 21.1 x -4.3 x -20.9 x 11.1 x 10.3 x 8.23 x
Yield - - - - - - - -
Capitalization / Revenue 0.63 x 0.63 x 0.56 x 0.68 x 0.74 x 0.99 x 0.96 x 0.93 x
EV / Revenue 2.11 x 2.06 x 1.87 x 1.91 x 1.79 x 1.91 x 1.7 x 1.51 x
EV / EBITDA 7.61 x 6.99 x 6.05 x 6.21 x 5.88 x 6.48 x 5.51 x 4.87 x
EV / FCF 17.4 x 53.8 x 126 x 27.4 x 33.6 x 11.2 x 9.7 x 8.55 x
FCF Yield 5.76% 1.86% 0.79% 3.65% 2.97% 8.94% 10.3% 11.7%
Price to Book 0.77 x 1.05 x 0.86 x 1.28 x 1.56 x 1.62 x 1.31 x 1.09 x
Nbr of stocks (in thousands) 1,092,089 1,095,972 1,103,007 1,110,645 1,120,971 1,132,641 - -
Reference price 2 9.800 9.650 8.010 9.120 10.44 13.81 13.81 13.81
Announcement Date 2/12/20 2/10/21 2/9/22 2/8/23 1/31/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 16,887 16,659 15,878 14,925 15,846 15,863 16,346 16,746
EBITDA 1 4,685 4,912 4,911 4,598 4,818 4,672 5,042 5,183
EBIT 1 4,142 4,388 4,401 4,139 4,361 4,249 4,516 4,718
Operating Margin 24.53% 26.34% 27.72% 27.73% 27.52% 26.79% 27.63% 28.17%
Earnings before Tax (EBT) 1 -1,265 -4,406 658 - -624 2,631 3,200 3,302
Net income 1 -999 -3,990 417 -2,353 -559 1,538 1,442 1,665
Net margin -5.92% -23.95% 2.63% -15.77% -3.53% 9.69% 8.82% 9.94%
EPS 2 -0.9100 -3.640 0.3800 -2.120 -0.5000 1.250 1.338 1.677
Free Cash Flow 1 2,053 638 236 1,042 842 2,706 2,862 2,956
FCF margin 12.16% 3.83% 1.49% 6.98% 5.31% 17.06% 17.51% 17.65%
FCF Conversion (EBITDA) 43.82% 12.99% 4.81% 22.66% 17.48% 57.91% 56.77% 57.03%
FCF Conversion (Net income) - - 56.59% - - 175.94% 198.48% 177.47%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/12/20 2/10/21 2/9/22 2/8/23 1/31/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 3,887 4,100 3,661 3,786 3,595 3,884 3,661 3,878 3,850 4,457 3,741 3,991 4,005 4,150 3,743
EBITDA 1 1,170 1,373 1,135 1,134 1,089 1,240 899 1,125 1,134 1,660 1,042 1,153 1,197 1,319 -
EBIT 1 1,042 1,248 1,013 1,019 977 1,130 785 1,011 1,020 1,546 916.6 1,033 1,079 1,164 1,027
Operating Margin 26.81% 30.44% 27.67% 26.91% 27.18% 29.09% 21.44% 26.07% 26.49% 34.69% 24.5% 25.87% 26.94% 28.06% 27.45%
Earnings before Tax (EBT) 1 - -175 -971 -1,160 - -1,100 - - 75 507 141 187 171 177 -
Net income 1 292 -159 -955 -232 56 -1,221 -205 -863 80 461 32 69 72.5 64.19 -
Net margin 7.51% -3.88% -26.09% -6.13% 1.56% -31.44% -5.6% -22.25% 2.08% 10.34% 0.86% 1.73% 1.81% 1.55% -
EPS 2 0.2600 -0.1400 -0.8600 -0.2100 0.0500 -1.100 -0.1800 -0.7700 0.0700 0.4100 -0.0482 -0.3959 0.002380 0.6734 -
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 10/27/21 2/9/22 5/3/22 7/26/22 11/3/22 2/8/23 5/10/23 8/2/23 11/8/23 1/31/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 24,932 23,742 20,878 18,411 16,607 14,623 12,118 9,618
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 5.322 x 4.833 x 4.251 x 4.004 x 3.447 x 3.13 x 2.404 x 1.856 x
Free Cash Flow 1 2,053 638 236 1,042 842 2,706 2,862 2,956
ROE (net income / shareholders' equity) 18.3% 11.8% 28.1% 30.9% 37.9% 27.5% 28.1% 25.3%
ROA (Net income/ Total Assets) 4.45% 5.24% 5.81% 6.13% 6.62% 6.01% 4.66% 4.63%
Assets 1 -22,466 -76,212 7,179 -38,354 -8,438 25,591 30,954 35,946
Book Value Per Share 2 12.80 9.160 9.320 7.110 6.710 8.550 10.50 12.70
Cash Flow per Share 2 0.6900 1.110 0.7200 1.430 1.220 2.300 2.390 2.450
Capex 1 525 578 562 548 526 512 543 554
Capex / Sales 3.11% 3.47% 3.54% 3.67% 3.32% 3.23% 3.32% 3.31%
Announcement Date 2/12/20 2/10/21 2/9/22 2/8/23 1/31/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Teva Pharmaceutical Industries Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
13.81 USD
Average target price
15.74 USD
Spread / Average Target
+13.95%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. TEVA Stock
  4. TEVA Stock
  5. Financials Teva Pharmaceutical Industries Limited